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Neurodegeneration is charac-terised by a progressive lossof neurons being the hall-
mark of a variety of neurodegenera-
tive diseases, including Amyotrophic
Lateral Sclerosis, Parkinson’s disease,
Alzheimer’s disease and Huntington’s
disease. 
Despite extensive research efforts, the
molecular mechanisms of neurodegen-
eration are still not comprehensively
understood, and the corresponding
diseases are incurable.
“From the discovery of the first soluble
proteases it took almost 150 years
before the first protease-targeting
drug entered the market. But 
today protease-targeting drugs are
indispensable in treatment of several
diseases, among them HIV, cancer and
hypertension.”
In recent years intramembrane pro-
teases have been implicated in emer-
gence of different neurodegenerative
diseases. This intriguing protease
family cleaves its substrates in the
plane of cellular membranes (read
more in the October 2018 edition of
Open Access Government), either
degrading their substrates or releasing
protein fragments capable of transfer-
ring signals across membranes (read
more in the January 2019 edition of
Open Access Government). 
The best studied intramembrane pro-
tease, in the context of neurodegener-
ation, is presenilin, an aspartyl
intramembrane protease that con-
tributes to the development of amyloid
plaques, one pathological hallmark of
Alzheimer’s disease. In contrast to all
other intramembrane proteases, 
presenilin requires the formation of a
protein complex to be active. 
Its partners in this complex, which is
termed γ-secretase, are the proteins
nicastrin, Aph-1 and Pen-2. Only if all
four partners assemble correctly, 
presenilin is active and cleaves its 
substrates, among them the β-Amy-
loid-Precursor Protein (APP), which
harbours the β-Amyloid peptide found
to aggregate in brains of Alzheimer’s
disease patients. Before APP is acces-
sible to γ-secretase it needs to be
cleaved by an independent protease in
its extracellular domain, which is
thereupon secreted. 
In principle, two proteases can medi-
ate this initial cleavage. If α-secretase,
represented by ADAM10, cleaves APP,
the β-Amyloid peptide is destroyed,
and γ-secretase liberates a peptide
that is not aggregating (non-amyloido-
genic processing). If β-secretase, rep-
resented by BACE-1, cleaves APP, the
subsequent cleavage by γ-secretase
liberates the β-Amyloid peptide (amy-
loidogenic processing) (Figure 1). The
cleavage of APP by γ-secretase, is not
precise, but liberates β-Amyloid pep-
tides of different length. This results
from multiple-cleavages of presenilin
in the transmembrane domain of its
substrate. A phenomenon that is also
observed for other intramembrane
proteases and commonly referred to
as processivity. 
The longer the β-Amyloid peptides, the
better they aggregate. Interestingly,
patients that carry mutations in one of
their presenilin genes produce more of
the longer β-Amyloid peptides and
suffer from early onset Alzheimer’s
Disease, also known as familial
Alzheimer’s disease (FAD), that is 
typically characterised by a more rapid
and aggressive progress. Based on
this, inhibition of presenilin to abolish
β-Amyloid peptide production or 
modulation of its processivity to favour
production of shorter β-Amyloid pep-
tides became an attractive treatment
strategy. 
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However, so far, all candidate drugs
tested in clinical studies failed to
improve the disease. Although this is
disappointing, it is unjustified to
dump presenilin as a drug target at
this stage. All clinical trials relied on
patients that already suffered from at
least mild cognitive impairment, but
changes in neuronal metabolism
occur long before clinical symptoms
can be observed. This implies that 
β-Amyloid reducing therapies must 
be applied even before patients are
diagnosed with dementia and in turn
requires the identification of valid
biomarkers that allow a reliable 
diagnosis of Alzheimer’s disease at a
very early stage. 
From basic research we also know
that, similar to other intramembrane
proteases, presenilin cleaves an exten-
sive spectrum of substrates, among
them the NOTCH receptor (read more
in the January 2019 edition of Open
Access Government), explaining why 
γ-secretase inhibition failed due to
serious side effects. 
“It is undisputed that intramembrane
proteases contribute to important
cellular pathways, which upon
malfunction cause severe diseases,
like neurodegeneration.” 
Moreover, another family of aspartyl
intramembrane proteases, the
SPP/SPPL proteases, shares its active
site architecture with γ-secretase, and
it is known that drugs targeting γ-sec-
retase can also affect this protease
family. However, physiological function
and substrate spectra of SPP/SPPL 
proteases have just recently began to
emerge (read more in the January 2019
and April 2019) editions of Open
Access Government). 
Another intramembrane proteases that
has been recently implicated in neu-
rodegeneration is PARL, an intramem-
brane serine protease that localises to
mitochondria. An altered turnover of
damaged mitochondria is part of the
reason why dopaminergic neurons die
and cause Parkinson’s disease. PARL
cleaves a mitochondrial protein, termed
PINK, that is implicated in this mito-
chondrial turnover and, thus, PARL is
suggested as a possible target for 
treatment of Parkinson’s disease. Cur-
rently this assumption, cannot be
tested since inhibitors, which selectively
163
PROFILE
Figure 1. Processing of APP (non-amyloidogenic to the left and amyloidigenic to the right), illustrated by Charlotte Spitz
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target PARL are not available. The
development of selective inhibitors
against intramembrane proteases is
challenging, since their cleavage 
mechanisms and the influence of 
the microenvironment present in the
membranes are poorly understood.
Also, the structures of intramembrane
proteases, which may facilitate the
development of inhibitors, are difficult
to solve and to date the structure of
only one human intramembrane 
protease and a limited number of
non-human homologues has been
solved. 
“The best studied intramembrane
protease, in the context of
neurodegeneration, is presenilin, an
aspartyl intramembrane protease that
contributes to the development of
amyloid plaques, one pathological
hallmark of Alzheimer’s disease.”
Furthermore, the biological function
of PARL in mitochondria has not been
unravelled and its whole substrate
spectrum has just begun to emerge,
which averts the prediction of poten-
tial side effects that may be caused by
PARL inhibition.
Accumulating evidence indicates the
neuroinflammation, which involves
microglia, contributes to the patho-
genesis of multiple neurodegenerative
diseases. In the peripheral immune
system, which includes all players of
the immune system outside the brain,
intramembrane proteases take on
important tasks (read more in the
April 2019 edition of Open Access
Government). Future studies will bring
to light whether this holds also true
for microglia, the representatives of
the immune system in brain.
From the discovery of the first soluble
proteases it took almost 150 years
before the first protease-targeting
drug entered the market. But today
protease-targeting drugs are indis-
pensable in treatment of several dis-
eases, among them HIV, cancer and
hypertension. Since intramembrane
proteases were discovered only about
20 years ago, it is not surprising, that
at present no drugs targeting these
enzymes are available. 
Nonetheless, it is undisputed that
intramembrane proteases contribute
to important cellular pathways, which
upon malfunction cause severe 
diseases, like neurodegeneration. If
sustained and unbiased research
approaches continue to better under-
stand these enzymes and their physi-
ological function, I am convinced 
that they will become valuable drug
targets, not only for treatment of 
neurodegenerative diseases but also
other, so for not curable diseases, way
before another 150 years have passed.
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